Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT04652609
Recruiting Not applicable

Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program

NCT04652609 · tracked via the Priya Life Science Spain tracker
Sponsor
Universidad de Granada
Phase
Not applicable
Started
2021-01-01
Last updated
2025-11-18

Condition(s) studied

Breast Neoplasm

Investigational drug(s) / intervention(s)

PRESIONA

PRESIONA: Aerobic and strength exercise combined with restricction blood flow cuffs during chemotherapy treatment

Study summary

The aim of this study is to determinate if therapeutic exercise with blood flow restriction (BFR) during neoadjuvant chemotherapy potentialy neurotoxic could prevent the onset of chemotherapy induced peripheral neuropathy (CIPN) comparing to usual care.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * 18 years or older * HER2+ breast cancer diagnosis * On the waiting list to anticancer medical treatment (taxanes-based neoadjuvant chemotherapy) Exclusion Criteria: * Previous diagnosis of cancer * Pregnant * Cardiac pathology * No symptoms or pathology that could be confused with neuropathy or related to diabetes * No recommendation from oncologist for therapeutic exercise practice

Primary outcome measure(s)

  • Patient-reported CIPN symptoms — Change from Baseline to 12 weeks (after intervention)
    Symptoms across to sensory, motor and automic domains will be measured using the questionnarie the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale. The total questionnaire has a score from 0 to 100, in which a higher score indicates increased symptom burden.

Trial sites (1)

FacilityCityRegionStatus
University of Granada Granada Spain Recruiting

More Universidad de Granada trials in Spain

Saffron Extract Supplementation and Sleep Quality in Middle-Aged Adults Recruiting
A Physical Activity Program for People With Heart Failure Enrolling by invitation
Adaptation of Human Brown Adipose Tissue to Calorie Restriction Active, not recruiting
Evaluation of Marginal Bone Loss and Associated Factors Around Ziacom Dental Implants With Different Prosthetic Connection Active, not recruiting
Chronic Grape Extract in Crosstraining Athletes: A Randomized Crossover Trial Starting soon

Other trials for the same condition

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04652609 on ClinicalTrials.gov ↗ ← All trials in Spain